Bevacizumab 사용 후 발생한 심한 허혈성 전대장염에서 대증적 요법으로 치료된 1예

• Published in: The Korean journal of gastroenterology pp. 42 - 46
• Main Authors: 이하니, 이명아, 김상우, 임예지, 이화영, 이혜민, 원혜성, 전상훈
• Format: Journal Article
• Language: Korean
• Published: 대한소화기학회 01.07.2011
• Subjects: 내과학
• ISSN: 1598-9992; 2233-6869

Bevacizumab (Avastin^Ⓡ) is a monoclonal antibody against the vascular endothelial growth factor (VEGF) receptor that increases the overall survival rate when added to standard chemotherapy regimens in patients with metastatic colorectal cancer. The known toxicities of bevacizumab are hypertension, proteinuria, wound healing complications, arterial thrombosis, bleeding,and gastrointestinal complications. Especially ischemic colitis can rapidly develop into bowel perforation, so an emergency operation often is needed. Recently, a 65-year-old male patient developed ischemic pancolitis after FOLFOX (85 mg/m^2 Oxaliplatin,d1; 200 mg/m^2 Leucovorin, d1; 400 mg/m^2 5-FU iv bolus, d1-2; and 600 mg/m^2 5-FU, d1-2, every two wk) and Bevacizumab combination chemotherapy was administered. However, he recovered after early conservative care without surgery. We report this case with a review of literature. KCI Citation Count: 1